CytoGenix and Aldevron Announce Positive Results of synDNA(TM) Hepatitis Vaccine Study.HOUSTON & FARGO, N.D. -- CytoGenix, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYGX) and Aldevron, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control announced positive results of a pilot study using CytoGenix synDNA(TM) as the active ingredient in a Hepatitis B vaccine hepatitis B vaccine n. Abbr. HB A vaccine prepared from the inactivated surface antigen of the hepatitis B virus and used to immunize against hepatitis B. , demonstrating that it is highly effective in generating an immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. . DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. vaccines are comprised of genes that confer immunologic protection by producing antigens without the need to expose the body to pathogenic organisms. For this study, CytoGenix scientists prepared a synthetic DNA vaccine derived from a plasmid provided by Aldevron that produces a Hepatitis B Hepatitis B Definition Hepatitis B is a potentially serious form of liver inflammation due to infection by the hepatitis B virus (HBV). It occurs in both rapidly developing (acute) and long-lasting (chronic) forms, and is one of the most common chronic viral surface antigen. Aldevron's scientists tested CytoGenix synDNA(TM) vaccine's activity in a rabbit model using Aldevron's proprietary Genetic Immunization immunization: see immunity; vaccination. and Antibody (GIA Noun 1. GIA - a terrorist organization of Islamic extremists whose violent activities began in 1992; aims to overthrow the secular Algerian regime and replace it with an Islamic state; "the GIA has embarked on a terrorist campaign of civilian massacres" (TM)) technology. Aldevron scientists compared levels of gene-specific serum immunoglobulin produced by the synDNA(TM) vaccine to its traditional plasmid DNA vaccine. The synDNA(TM) vaccine generated immunoglobulin levels in the test animals up to five times greater than a comparable plasmid DNA vaccine produced by bacterial fermentation. Frank Vazquez, CytoGenix, Inc.'s Executive Vice President and COO, commented, "These results are very important because they confirm the effectiveness of synDNA(TM) that we have seen in other animal studies of DNA vaccines. It is clear that our synDNA(TM) process produces bio-active DNA. This latest result is a major step forward in our efforts to accelerate CytoGenix' Rapid Response Vaccine Development Program against H5N1 avian flu, smallpox and other infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. targets." Michael Chambers, Aldevron President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , stated, "Aldevron has supported the DNA vaccine field for the past seven years by providing quality DNA, antibody and protein products as well as by sponsoring scientific forums and maintaining the DNAvaccine.com web site. The synDNA(TM) process is potentially a big step forward in the DNA vaccine and gene medicine fields. We look forward to expanding Aldevron-CytoGenix scientific and business collaboration." About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology. About Aldevron: With facilities in the United States and Europe, Aldevron offers products and services to DNA vaccine and gene therapy scientists. These include contract bio-manufacturing, genetic immunization and antibody production, and a complete line of gene therapy plasmids. More information can be found at http://www.aldevron.com. SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion